Founders
Paolo Fiorina
Scientific Founder
Francesca D’Addio
Scientific Founder
Paolo Fiorina
Scientific Founder
With extensive research and advisory experience from a number of roles in both academia and industry, Paolo has made significant and innovative contributions to the fields of autoimmune diabetes, islet transplantation and diabetic nephropathy. After studying transplantation immunology for six years at the San Raffaele Scientific Institute, Paolo joined Boston Children’s Hospital as a research fellow and became an Assistant Professor of Nephrology at Boston Children’s/Harvard Medical School. He has recently been nominated Associate Professor in Endocrinology at the University of Milan, and currently acts as Chief of Endocrinology at Fatebenefratelli-Sacco-Melloni Hospitals.
Paolo is also founder and CSO of Enthera Pharmaceuticals, a biotech company developing first-in-class biologics for selected autoimmune conditions.
Paolo obtained a medical degree from the University of Milan in 2004. He continued his training through a combined Internal Medicine/PhD program in Immunology at Parma University.
Francesca D’Addio
Scientific Founder
Francesca obtained her medical degree and residency in Nephrology from the University of Bologna, and joined an exchange PhD program in Nephrology and Transplant Immunology at the Harvard Medical School (Boston, USA). After a 2-year fellowship at Harvard Medical School, Transplant Research Center, Brigham and Women’s Hospital and Children’s Hospital, Francesca moved to Italy and joined the Transplantation division at San Raffaele Hospital in Milan. In 2013, a 3-year postdoctoral fellowship in Molecular Medicine brought Francesca back to Boston where she joined Prof. Fiorina’s lab at Boston Children’s Hospital.
Francesca is Head of Preclinical Research of Enthera Pharmaceuticals, a biotech company developing first-in-class biologics for selected autoimmune conditions, of which she is also founder.
Francesca has been Assistant Professor in Endocrinology at the University of Milan since 2016.